Chondrosarcoma - Pipeline Insight, 2021

Researcher’s, “Chondrosarcoma - Pipeline Insight, 2021,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Chondrosarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Chondrosarcoma Understanding
Chondrosarcoma: Overview
Chondrosarcoma is a malignant tumor composed of cartilage-producing cells. It is the second most common primary malignancy of bone, and one of the most difficult bone tumors to diagnose and treat. They are most commonly found in older patients within the long bones and can arise de novo or secondary from an existing benign cartilaginous neoplasm. Symptoms of chondrosarcoma may vary depending on the location of the tumor. Patients usually present with pain, pathological fracture, a palpable lump or local mass effect. Hyperglycemia can occur as a paraneoplastic syndrome. A bone tumor is often first diagnosed on x-ray after a physical examination. Additional tests, including a bone scan, CT scan, MRI and PET scan, can provide more information about the tumor. Ultimately, biopsy of the tumor is the way to make a definite diagnosis of chondrosarcoma. The treatment of conventional chondrosarcoma is surgical. The response of chondrosarcomas to chemotherapy and radiation therapy is limited. Physical therapy helps to regain strength and use of the affected area after surgery.

"Chondrosarcoma - Pipeline Insight, 2021" report by Researcher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chondrosarcoma pipeline landscape is provided which includes the disease overview and Chondrosarcoma treatment guidelines. The assessment part of the report embraces, in depth Chondrosarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chondrosarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Chondrosarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Chondrosarcoma.

Chondrosarcoma Emerging Drugs Chapters
This segment of the Chondrosarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chondrosarcoma Emerging Drugs
• INBRX-109: Inhibrx
INBRX-109 is a humanized recombinant tetravalent single domain IgG1 antibody targeting the human death receptor 5. INBRX-109 is a precisely engineered tetravalent sdAb-based therapeutic candidate currently being evaluated in patients diagnosed with chondrosarcoma, mesothelioma, pancreatic adenocarcinoma, gastric adenocarcinoma, and synovial sarcoma. INBRX-109 agonizes DR5 to induce tumor selective programmed cell death.

• Ifosfamide: Atlanthera
Ifosfamide is a DNA cross-linking agent and an inhibitor of DNA synthesis. It is being developed by Atlanthera for the treatment of osteosarcoma, chondrosarcoma, and ewing’s sarcoma. The drug is currently in preclinical studies.
Further product details are provided in the report……..

Chondrosarcoma: Therapeutic Assessment
This segment of the report provides insights about the different Chondrosarcoma drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Chondrosarcoma
There are approx. 6+ key companies which are developing the therapies for Chondrosarcoma. The companies which have their Chondrosarcoma drug candidates in the most advanced stage, i.e. Phase I include, Inhibrx.

• Phases
Researcher’s report covers around 6+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Chondrosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chondrosarcoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Chondrosarcoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chondrosarcoma drugs.

Chondrosarcoma Report Insights
• Chondrosarcoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chondrosarcoma Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Chondrosarcoma drugs?
• How many Chondrosarcoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chondrosarcoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chondrosarcoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chondrosarcoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Roche
• ImmunityBio
• Inhibrx
• AnHeart Therapeutics
• Atlanthera

Key Products
• Vismodegib
• Aldox
• INBRX-109
• AB 218
• Ifosfamide